Future Market Insights opines that polysorbate-80 demand is being reshaped by two parallel forces: the biosimilar approval pipeline, which requires high-purity excipient supply at pharmaceutical scale, and tightening oxidative impurity standards under the revised USP monograph, which is compressing the number of qualified suppliers.